China CDMO Contract Manufacturing Manufacturers & Supplier

Generalist synthetic pharmaceutical CDMOs are primarily built around pure, single-component small molecules and struggle with the complex, multicomponent matrices of botanical extracts. Natural product matrices contain hundreds of co-eluting compounds, complex tannins, and delicate terpenes that undergo degradation during conventional processing. A dedicated botanical CDMO like MedGence brings 14+ years of specialized chromatographic expertise, purpose-built macroporous resin purification systems, low-temperature vacuum concentrators, and validated HPTLC/HPLC fingerprinting libraries. This specialized infrastructure enables us to maintain batch-to-batch chemical consistency and biological activity that generalist CDMOs cannot replicate.

We address seasonal and geographical variation through our proprietary Agro-Origin Yield Mapping Protocol. Because identical botanical species vary dramatically in active secondary metabolites based on altitude, soil composition, and harvest timing, we establish standardized quality profiles across China's major cultivation regions. We map the peak seasonal window for every target active molecule. If natural climate fluctuations reduce active percentages in one region, our multi-province GAP sourcing network enables us to blend or source from complementary authenticated growing zones to consistently hit client target active ingredient specifications.

Our central analytical laboratory utilizes high-performance thin-layer chromatography (HPTLC) for photographic visual identity, high-performance liquid chromatography coupled with diode-array detection and tandem mass spectrometry (HPLC-DAD-MS/MS) for marker quantification, and gas chromatography (GC-FID/MS) for volatile terpenes and residual solvents. Safety profiling includes inductively coupled plasma mass spectrometry (ICP-MS) for heavy metals (Lead, Arsenic, Cadmium, Mercury), automated multi-residue pesticide screens covering 400+ compounds under USP <561> and EP 2.8.13, and comprehensive microbial testing using rapid PCR and bioburden enumeration.

We operate exclusively as a fee-for-service entrusted research and contract manufacturing partner. All proprietary extraction parameters, custom formulation designs, analytical methodologies, and clinical data generated during the project remain the client's sole intellectual property. Operations are protected by comprehensive bilateral non-disclosure agreements with specific Chinese and international jurisdiction clauses. Physically, proprietary projects are run in secure cleanrooms with access restricted to assigned personnel. All digital analytical records and batch reports are secured on isolated servers with immutable audit logs following ALCOA+ data integrity standards.

Yes. We design and execute clinical programs customized to your specific regulatory targets. For premium nutraceutical and dietary supplement brands seeking substantiated structure/function claims, we execute randomized, double-blind, placebo-controlled human proof-of-concept trials (typically 30–120 participants). For clients pursuing botanical drug filings (such as FDA Botanical Guidance or China NMPA Class 1.1/2.3 innovative natural medicines), we partner with accredited GCP clinical trial sites to execute comprehensive Phase I pharmacokinetic/tolerability studies through Phase II/III multicenter efficacy and long-term safety studies.

Our cleanroom facilities can manufacture a wide variety of bulk extracts and finished commercial dosage forms. For active raw materials, we supply standardized dry extract powders, spray-dried water-soluble granules, concentrated liquid extracts, and CO2 supercritical volatile oils. For finished retail dosages, we operate high-speed automated lines for hard gelatin and vegetarian HPMC capsules, softgels with oily or paste suspensions, dual-action coated tablets, oral liquid ampoules/syrups, and single-serve soluble powder sachets, all packaged under cGMP conditions.